Thu. Aug 18th, 2022
CureVac#39;s COVID-19 vaccine triggers immune response in Phase I trial CureVac – backed by German biotech investor Dietmar Hopp, the Gates Foundation and GlaxoSmithKline – said volunteers developed a level of neutralising antibodies on par with people who had recovered from a serious case of COVID-19.